MaxCyte (MXCT) vs OneMedNet (ONMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
MaxCyte (MXCT) has outperformed OneMedNet (ONMD) over the past year, losing 32.9% versus a loss of 81.1%. Over five years, MXCT leads with a -90.6% price change compared with -95.1% for ONMD. MaxCyte is the larger company by market cap ($107.3 million vs $28.6 million), about 3.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | ONMD |
|---|---|---|
| Share price | $1.04 | $4.91 |
| Market cap | $107.33M | $28.60M |
| 1-day change | -4.59% | -1.21% |
| YTD return | -32.90% | -55.36% |
| 1-year return | -32.90% | -81.12% |
| 5-year return | -90.57% | -95.12% |
| EPS (TTM) | $-0.34 | $-1.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.87 | $42.20 |
| 52-week low | $0.643 | $4.90 |
| Distance from 52-week high | -44.24% | -88.36% |
| Average volume | 699.83K | 114.65K |
| Shares outstanding | 103.21M | 5.82M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MaxCyte is about 3.8 times larger than OneMedNet by market value ($107.33M vs $28.60M).
- MXCT has outperformed ONMD by 48.2 percentage points over the past year.
MXCT vs ONMD FAQ
Which is bigger, MaxCyte or OneMedNet?
MaxCyte (MXCT) is larger, with a market capitalization of $107.33M compared with $28.60M for OneMedNet (ONMD).
Which stock has performed better over the past year, MXCT or ONMD?
MXCT returned -32.90% over the past 12 months, compared with -81.12% for ONMD (price return, excluding dividends). Past performance does not predict future results.
Are MaxCyte and OneMedNet in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.